National Coverage Determination: Pre-exposure Prophylaxis Using Antiretroviral Drugs to Prevent HIV Infection

CMS announced the posting of a proposed National Coverage Determination for Pre-Exposure Prophylaxis (PrEP) Using Antiretroviral Drugs to Prevent Human Immunodeficiency Virus (HIV) Infection. CMS proposes coverage of PrEP using antiretroviral drugs (whether oral or injectable) approved by the FDA to prevent HIV infection in individuals at high risk of HIV acquisition. CMS also proposes to cover the administration of injectable PrEP using antiretroviral drugs to prevent HIV infection.

Source: https://www.cms.gov/outreach-and-education/outreach/ffsprovpartprog/provider-partnership-email-archive/2023-07-13-mlnc#_Toc140123836